Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772577 | 0.92 | PIK3CD (0.50) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL298010 | 0.82 | CYP1A2 (0.54) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL23823660 | 0.80 | CYP1A2 (0.64) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL860793 | 0.79 | CYP1A2 (0.77) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL37407 | 0.79 | — | — | |
| SCHEMBL14407779 | 0.79 | CYP1A2 (0.77) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL1259582 | 0.78 | PIK3CD (0.59) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL1259584 | 0.78 | PIK3CD (0.59) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL84934 | 0.78 | PIK3CD (0.59) | PIK3CDCYP1A2TDP1HRH3KDM4E | |
| SCHEMBL772555 | 0.77 | BLM (0.46) | SMN1; SMN2ALDH1A1DRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611856-B | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-07-05 | — | — | CN | claimed |
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-4345096-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2024-04-03 | — | — | EP | claimed |
| CN-117642389-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2024-03-01 | — | — | CN | claimed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| WO-2023284834-A1 | PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 宜昌人福药业有限责任公司 | 2023-01-19 | — | — | WO | claimed |
| CN-115611856-A | Piperidine derivative and pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2023-01-17 | — | — | CN | claimed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| EP-1838712-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| WO-2007059323-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| WO-2007059113-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| EP-1784180-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-16 | — | — | EP | claimed |
| WO-2006064196-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| WO-2006029115-A2 | 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | claimed |
| EP-0131374-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PENEM DERIVATIVES | PFIZER INC. (US) | 1988-11-23 | — | — | EP | claimed |
| US-4619783-A | BACTERICIDES | PFIZER INC. (US) | 1986-10-28 | — | — | US | claimed |
| EP-0131374-A1 | Process and intermediates for the preparation of penem derivatives | PFIZER INC. (US) | 1985-01-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | PIK3CD 2334/4885CYP1A2 1563/4885TDP1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.